Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.46 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134232 | 0.92 | KMT2A (0.60) | HPGDPKMALDH1A1KMT2AMEN1 | |
| SCHEMBL12235840 | 0.81 | HPGD (0.62) | HPGDPKMSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1757570 | 0.76 | SMN1; SMN2 (0.66) | HPGDPKMSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9798486 | 0.75 | HPGD (0.63) | HPGDPKMSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL17427523 | 0.74 | HPGD (0.50) | HPGDSMN1; SMN2ALDH1A1MAPTNPC1 | |
| SCHEMBL17875267 | 0.74 | PKM (0.64) | HPGDPKMSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL11453214 | 0.74 | HPGD (0.55) | HPGDPKMSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL11327841 | 0.74 | HPGD (0.58) | HPGDPKMSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL7309985 | 0.73 | PLIN1 (0.49) | HPGDALDH1A1MAPTRAB9APLIN1 | |
| SCHEMBL12948859 | 0.72 | PKM (0.63) | HPGDPKMSMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10071110-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-09-11 | — | — | US | disclosed |
| US-20170239279-A1 | PHOSPHONATE COMPOUNDS | UNIV CALIFORNIA (US) | 2017-08-24 | — | — | US | disclosed |
| US-9649321-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160067268-A1 | PHOSPHONATE COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-10 | — | — | US | disclosed |
| US-9206208-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150051174-A1 | Phosphonate Compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-19 | — | — | US | disclosed |
| US-8889658-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-18 | — | — | US | disclosed |
| EP-1914237-B1 | Phosphonate ester antiviral compounds | UNIV CALIFORNIA (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8710030-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-04-29 | — | — | US | disclosed |
| US-20140045794-A1 | Phosphonate Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-13 | — | — | US | disclosed |
| US-7094772-B2 | guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-08-22 | — | — | US | disclosed |
| US-7034014-B2 | New derivatives of cidofovir, adefovir, cyclic cidofovir or tenofovir made by forming phosphonate ester with an alcohol such as alkylglycerol, alkylpropanediol, 1-S-alkylthioglycerol, alkoxyalkanol or alkylethanediol; e.g. 1-O-octadecylpropanediol-3-cidofovir; side effect reduction, less toxic; antiviral | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-04-25 | — | — | US | disclosed |
| US-20050182019-A1 | An antiviral nucleoside in which the 5'-hydroxyl group has been substituted for a phosphonate or methyl phosphonate that is covalently linked to an alkylethanediol; osteoporosis; anticarcinogenic agents; viricides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-08-18 | — | — | US | disclosed |
| US-20050176673-A1 | guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-08-11 | — | — | US | disclosed |
| US-20040127735-A1 | New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-07-01 | — | — | US | disclosed |
| US-6716825-B2 | OSTEOPOROSIS AND OTHER DISORDERS OF BONE METABOLISUM, CANCER, VIRAL INFECTIONS, AND THE LIKE. | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-04-06 | — | — | US | disclosed |
| US-20040019232-A1 | Analogs of phosphonate and bisphosphonate compounds based on bone resorption suppressors (alendronic acid), viricides (cidofovir) and antineoplastic agents (bemcitabine); nontoxic; bioavailability; side effects reduction | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| EP-1233770-A4 | PHOSPHONATE COMPOUNDS | UNIV CALIFORNIA AT SAN DIEGO (US) | 2003-04-16 | — | — | EP | disclosed |
| EP-1233770-A2 | PHOSPHONATE COMPOUNDS | The Regents of The University of California at San Diego (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001039724-A2 | PHOSPHONATE COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051174-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | HPGD 1030/4885PKM 285/4885SMN1; SMN2 2978/4885 |
| US-20140045794-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | HPGD 1030/4885PKM 285/4885SMN1; SMN2 2978/4885 |
| US-20050176673-A1 | guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections | ENPP1, ADA, ENTPD5 | HPGD 2232/4885PKM 2102/4885SMN1; SMN2 4244/4885 |
| US-10071110-B2 | Phosphonate compounds | PHPT1, PHOSPHO1, PIK3CA | HPGD 1030/4885PKM 285/4885SMN1; SMN2 2978/4885 |
| US-20040127735-A1 | New phosphonate ester derivatives of drugs such as antivirals cidofovir, adefovir, tenofovir, azidothymidine (AZT), or bisphosphonates such as alendronate, or anticancers such as cytosine arabinoside; side effect reduction, less toxic; antiviral | TYMP, ADA, DCTD | HPGD 3827/4885PKM 2423/4885SMN1; SMN2 3729/4885 |
| US-20040019232-A1 | Analogs of phosphonate and bisphosphonate compounds based on bone resorption suppressors (alendronic acid), viricides (cidofovir) and antineoplastic agents (bemcitabine); nontoxic; bioavailability; side effects reduction | BPGM, PPA1, INPP5D | HPGD 1682/4885PKM 2524/4885SMN1; SMN2 3446/4885 |
| US-20170239279-A1 | PHOSPHONATE COMPOUNDS | PHPT1, PHOSPHO1, PIK3CA | HPGD 1030/4885PKM 285/4885SMN1; SMN2 2978/4885 |
| US-20160067268-A1 | PHOSPHONATE COMPOUNDS | PHPT1, PHOSPHO1, PIK3CA | HPGD 1030/4885PKM 285/4885SMN1; SMN2 2978/4885 |
| US-20050182019-A1 | An antiviral nucleoside in which the 5'-hydroxyl group has been substituted for a phosphonate or methyl phosphonate that is covalently linked to an alkylethanediol; osteoporosis; anticarcinogenic agents; viricides | MTAP, SAMHD1, NT5C3B | HPGD 421/4885PKM 3057/4885SMN1; SMN2 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.